Zongertinib in HER2-altered breast cancer: Preclinical activity and preliminary results from a phase Ia dose-escalation study. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I.

Estimation of overall survival in immunotherapy-treated bladder cancer using computer vision. This is an ASCO Meeting Abstract from the 2025 ASCO Genitourinary Cancers Symposium. This abstract does ...

Gustave Roussy partners with One Biosciences, a techbio company that harnesses single cell technology and AI to develop advanced precision diagnostics. The collaboration aims to further demonstrate ...